• MicroRNA 424/503 Regulates TGF-β-Induced Cell Cycle Arrest i

  2026-06-25

  This study reveals that the microRNA 424/503 cluster is a critical mediator of TGF-β-induced cell cycle arrest in mammary epithelial cells by posttranscriptionally downregulating CDC25A. The findings deepen mechanistic understanding of TGF-β/Smad signaling in epithelial cytostasis and suggest new avenues for modulating cell proliferation in hormone receptor-positive breast tissue.

• Faropenem Sodium: Protocols and Best Practices for AMR Resea

  2026-06-25

  Faropenem sodium stands out for its robust inhibition of bacterial cell wall synthesis and oral bioavailability, making it ideal for translational and antimicrobial resistance (AMR) research. This guide details experimental workflows, troubleshooting, and data-driven advantages—empowering researchers to model Gram-positive, Gram-negative, and anaerobic infections with confidence.

• Thrombin B Chain Fragment: Decoding Protease Specificity for

  2026-06-24

  Explore how the Coagulation Factor II (Thrombin) B Chain Fragment advances assay specificity and mechanistic insight in blood coagulation research. This in-depth analysis integrates primary evidence on trypsin-like serine protease selectivity and bridges key knowledge gaps for vascular and platelet biology.

• SR-202 (PPAR Antagonist): Redefining Insulin Resistance Rese

  2026-06-23

  Explore how SR-202, a selective PPARγ antagonist, enables advanced insulin resistance and obesity research through precise modulation of adipogenesis and immune pathways. This article delivers a data-driven, mechanistic analysis and distinct translational insights beyond standard application guides.

• EZ Cap™ EPO mRNA: Optimizing Neurorepair & Erythropoiesis Wo

  2026-06-23

  EZ Cap™ EPO mRNA (ψUTP) from APExBIO empowers efficient, low-immunogenicity delivery of human erythropoietin mRNA for advanced neurorepair and erythropoiesis research. This guide distills experimental workflows, troubleshooting strategies, and innovations that leverage the latest targeted mRNA delivery advances.

• Anti-b Suppresses Hyperlipidaemia via mTOR/PPARγ and SREBP1

  2026-06-22

  This study identifies Anti-b as a selective mTOR modulator that diminishes hyperlipidaemia and hepatic steatosis in rodent models by downregulating mTOR/PPARγ and mTOR/SREBP1 signaling. The findings provide mechanistic insights into lipid metabolism regulation and highlight new directions for therapeutic intervention in metabolic disorders.

• Norovirus Co-opts NINJ1 for Selective Viral Protein Secretio

  2026-06-22

  Song et al. uncover a novel mechanism by which murine norovirus exploits the host factor NINJ1 to enable selective secretion of the viral NS1 protein during infection. This discovery reshapes our understanding of plasma membrane rupture, DAMP release, and the molecular interplay between viral and host factors in programmed cell death.

• Scenario-Driven Solutions for Reliable mTOR Activation: MHY1

  2026-06-21

  This article offers a scenario-driven, evidence-based guide to optimizing mTOR pathway and autophagy assays using MHY1485 (SKU B5853). Through realistic laboratory Q&A, we address experimental design, protocol optimization, data interpretation, and vendor selection—highlighting how MHY1485 from APExBIO enables reproducible, high-impact results in cell viability, proliferation, and ovarian follicle development studies.

• Streptavidin-FITC: Precision Fluorescent Detection Workflows

  2026-06-20

  Leverage Streptavidin-FITC for high-sensitivity detection and quantitation of biotinylated molecules across immunofluorescence, flow cytometry, and nanoparticle trafficking. Discover protocol refinements, troubleshooting tactics, and translational insights directly informed by the latest lipid nanoparticle trafficking research.

• Single-Cell-Type Spatial Proteomics via PSPro: Innovations a

  2026-06-19

  The reference study introduces PSPro, a proximity labeling strategy that enables all-at-once spatial proteome profiling of complex tissue at single-cell-type resolution. By optimizing antibody-guided biotinylation and affinity purification, the authors achieve robust detection of thousands of proteins across diverse cell types, revealing spatial heterogeneity within tissue microenvironments.

• BMS-345541: Strategic IKK-1/2 Inhibition for Translational I

  2026-06-19

  This thought-leadership article explores the mechanistic and translational significance of BMS-345541 (free base), a potent and selective IKK-1/IKK-2 inhibitor. Framed for advanced researchers, it connects molecular insight, experimental rigor, and strategic positioning in inflammation, angiogenesis, and cancer research—drawing on recent cross-domain findings and protocol best practices.

• Salvianolic Acid B: Mechanistic Innovation and Assay Design

  2026-06-18

  Explore the unique role of Salvianolic acid B as an advanced pulmonary fibrosis research compound. This article delivers a mechanistic deep-dive and practical assay insights not found in previous reviews.

• I-BET-762: Potent BET Inhibitor for Epigenetic and Inflammat

  2026-06-18

  I-BET-762 is a selective BET inhibitor with nanomolar affinity, validated for robust anti-inflammatory and transcriptional regulatory effects. Recent evidence shows it drives ferroptosis in various cell types, supporting its use in cancer biology and preclinical inflammatory models.

• Thrombin as a Trypsin-like Serine Protease in Fibrin-Based A

  2026-06-17

  Harness the specificity of the Coagulation Factor II (Thrombin) B Chain Fragment [Homo sapiens] to model fibrinogen-to-fibrin conversion and platelet activation with unmatched reproducibility. This guide distills protocol optimizations, advanced vascular modeling use-cases, and troubleshooting tips grounded in the latest angiogenesis and proteolysis research.

• Targeting LH2 with Salvianolic Acid B to Mitigate Pulmonary

  2026-06-17

  This study delineates Salvianolic acid B’s capacity to inhibit lysyl hydroxylase 2 (LH2), curtailing collagen cross-linking and extracellular matrix remodeling in pulmonary fibrosis. By integrating mechanistic, in vitro, and in vivo data, the research establishes Salvianolic acid B as a potent, natural antifibrotic agent targeting key molecular pathways.

16673 records 1/1112 page Next 12345 下5页 Last page